Protego Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- Protego Biopharma's estimated annual revenue is currently $3.2M per year.
- Protego Biopharma's estimated revenue per employee is $77,500
- Protego Biopharma's total funding is $51M.
Employee Data
- Protego Biopharma has 41 Employees.
- Protego Biopharma grew their employee count by 28% last year.
Protego Biopharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-founder, VP Biology | Reveal Email/Phone |
2 | VP Chemistry | Reveal Email/Phone |
3 | Executive Assistant | Reveal Email/Phone |
Protego Biopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Protego Biopharma?
Protego Biopharma focuses on developing therapeutics and companion diagnostics targeting protein misfolding diseases.
keywords:N/A
$51M
Total Funding
41
Number of Employees
$3.2M
Revenue (est)
28%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Protego Biopharma News
2022-04-19 - Cassava Sciences Hits Back at NYT For Alleged "Pre-Set ...
He noted that one of the critics cited was behind the $51 million Series A financing for Protego Biopharma, which is focused on developing...
2022-04-17 - Cassava Sciences responds to simufilam study allegations in The New York
Times
Cassava wrote that Bredt's former employer, MPM Venture Capital, co-led a $51 million investment in a startup Protego Biopharma that focuses...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.9M | 41 | N/A | N/A |
#2 | $4.8M | 41 | 0% | N/A |
#3 | $3.2M | 41 | 28% | $43M |
#4 | $8.2M | 41 | 11% | N/A |
#5 | $3.9M | 41 | 11% | N/A |